Available presentations and abstracts from the following ECAT Participants’ Meetings:
13th ECAT International Symposium 2024
12th ECAT International Symposium 2022
11th ECAT International Symposium 2018
Satellite Symposium 2018
10th ECAT International Symposium 2016
9th ECAT International Symposium 2014
8th ECAT International Symposium 2012
7th ECAT International Symposium 2010
6th ECAT International Symposium 2008
13th ECAT International Symposium 2024
| Speaker | Titel | More Information |
| D. Lillicrap | Personalised medicine in thrombosis and haemostasis |  |
| E. Lindhoff-Last | Anti-PF4 induced thrombotic disorders (APIT) | |
| T. van Duijl | Novel Mass Spectrometry-based technologies for coagulation diagnostics | |
| P. Tsiamyrtzis | Modern approaches in statistical process control for IQC and EQA | |
| P. Meijer | New EQA approaches: From analytical to diagnostic performance | |
| F. Mullier | The consequences of the IVDR for laboratories | |
| Y. Henskens | Flow-chamber-based platelet analysis | |
| C. Orlando | Current practice in thrombophilia testing: from phenotype to genotype | Not available |
| N. van Es | Factor XI inhibitors: the holy grail of antithrombotic treatment? | |
| R. Urbanus | Nanobodies as potential tools for platelet diagnostics | |
| P. Meijer | Results of Light Transmission Aggregometry pilot survey | |
| P. Bossuyt | Haverkate Lecture: When can we guarantee that a test is fit for purpose? | |
| K. Vanhoorelbeeke | TTP: pathophysiology and diagnosis | Not available |
| M. van Essen | Laboratory testing for ADAMTS13: What can we learn from EQA data? | |
| A. Huisman | Is the new ACR/EULAR for Antiphospholipid antibody testing fit-for-purpose? | |
| L. van Hoovels | Harmonization of antiphospholipid antibody test results? | |
| D. Lillicrap | New developments in haemophilia treatment | |
| E. Göttgens | Long-term evaluation of FVIII and FIX testing | |
| S. Davidson | Inhibitors in rare bleeding disorders | |
| K. Devreese / G. Moore | Debate: Is the Lupus Anticoagulants testing dogma perfect? | |
| M. Nagler | Application of artificial intelligence in hemostasis | |
| M. Roest | Whole blood thrombin generation to study the risk of thrombosis in cancer | |
| W. van Heerde | Whole blood analyses: what do we miss by measuring in blood plasma? | |
12th ECAT International Symposium 2022
Dear participant, due to a technical problem, Friday’s videos are not available. We apologize for the inconvenience.
| Speaker | Titel | More Information |
| A. Greinacher | HIT and VITT: is there a bridge? | |
| G. Lippi | COVID-19 and the role of the haemostasis laboratory | |
| M. van Schrojenstein Lantman | Determination of lot-to-lot variability of reagents | |
| C. Cobbaert | What are the implications of the new IVD regulation for the daily laboratory practice? | |
| J. Douxfils | Method validation for haemostasis assays | |
| D. Gommers | The intensive care unit during the COVID-19 pandemic | |
| J. Coutinho | Sinus thrombosis, past, present and future | |
| P. Meijer | Guidance for FVIII/FIX Inhibitor testing | |
| M. van Essen | Biological Variation in haemostasis | |
| G. Moore | When Haemostasis Assays Mislead | |
| F. Leebeek | Hemophilia and gene therapy | |
| R. Selby | D-Dimer: quality of laboratory testing and its implications in clinical practice | |
| P. Tsiamytzis / P. Meijer | How to interpret the Z-score in survey reports (theory and practical examples) | |
| K. Freson | Thrombogenomics | |
| J. Eikenboom | Low von Willebrand Factor and diagnostic treshold | |
| M. Kruijt | Next-generation antithrombin diagnostics by mass spectrometry | |
| M. Coppens / S. Kitchen | What information does the doctor expect from the laboratory? What kind of services can a laboratory deliver to the physician? | |
| G. Jansen | Follow-up of LA positieve patients | |
| K. Devreese | Antiphospholipid Antibody Assay results and clinical implications | |
11th ECAT International Symposium
| Speaker | Titel | More Information |
| D. Lillicrap | New developments in haemophilia treatment | |
| S. Tiefenbacher | Haemophilia treatment and laboratory testing | |
| L. Schutte | One-stage clotting assay versus chromogenic testing in the diagnosis of haemophilia patients | |
| I. van Moort | Factor VIII testing: results of ECAT surveys | |
| E. Katona | Inherited FXIII deficiency: laboratory diagnosis | |
| H. Versteeg | Crossroads between cancer and coagulation | |
| E. Azjner | EFLM/EQALM on the laboratory diagnosis of a prolonged APTT | |
| K. Devreese | Thrombotic APS pathophysiology: consequences for laboratory diagnosis | |
| R. Urbanus | Interferences in Lupus testing | |
| D. Coen Herak | Autovalidation of coagulation test results | |
| R. Idema | Biological variation, quality specifications and Six Sigma | |
| K. Kluft | A paradigm shift in measuring blood coagulation | |
| G. Moore | The use of snake venoms in the coagulation laboratory | |
| T. Kitchen | The importance of thromboelastography in clinical practice | |
| M. de Maat | Is there a need to measure ROTEM/TEG | |
| P. Meijer | Results of ECAT EQA programme on ROTEM/TEG | |
| A. McCormick | Platelet Function Testing | |
| P. Tsiamyrtzis | How to evaluate your Z-score? | |
| P. Meijer | New developments within ECAT | |
| E. Lindhoff – Last | Is laboratory measurement of DOACS necessary? | Not available |
| R. Gosselin | Guidance for laboratory testing of DOACS | |
| J. Douxfils | Interference of DOACS in coagulation tests | |
| M. van Essen | Results of ECAT EQA programme on DOACS | |
| Speaker | Titel | More Information |
| D. Lillicrap | Treatmentof patients with extended half-life FVIII and FIX products | |
| E. Gray | Potency labelling of extended half-life FVIII and FIX products | |
| S. Tiefenbacher | Laboratory measurement of extended half-life FVIII | |
| S. Kitchen | Laboratory measurement of extended half-life FIX | |
| I. Jennings | Quality Assurance of extended half-life products | |
| P. Meijer | Future perspective in quality assurance | |
10th ECAT International Symposium 2016
| Speaker | Titel | More Information |
| H. van Ommen | Developmental haemostasis: consequences for clinical practice | |
| G. Lippi | Diagnostics in venous thromboembolism: from origin to future prospects | |
| R. Marlar | Laboratory Guidelines for Antithrombin, Proteins C and S, and APC-Resistance Testing | |
| E. Castoldi | TFPI: new insights in an old inhibitor | |
| C. Maas | The role of contact activation in thrombosis and beyond | |
| C. Kluft | Is standardisation in coagulation feasible? | |
| E. Gray | Have international standards in haemostasis improved comparability of laboratory results? | |
| T. v.d. Besselaar | International Normalized Ratio for monitoring therapy with vitamin K Antagonists | |
| F. Leebeek | The diagnosis of von Willebrand Disease | |
| S. Sandberg | Analytical Performance Specifications: the benefit for the laboratory! | |
| P. Mannucci | The differential diagnosis between TTP and atypical HUS | |
| A. H. Kristoffersen | Current practice in the pre-analitycal phase | |
| S. Kitchen | The use of Guidelines in Haemostasis Laboratory Testing | |
| K. Meijer | Haemophilia, new development in patient treatment | |
| R. Pruthi | Introduction on Inhibitor Testing | |
| P. Meijer | ECAT: Towards sustainable EQA | |
| T. Lisman | The relevance of pre-operative hemostasis screening | |
| J. Meijers | Medical device thrombosis | |
| M. ter Horst | Rotem, does it have value at the cardiothoracic operation theatre? | |
| D. James | How to use EQA results within the laboratory | |
9th ECAT International Symposium 2014
| Speaker | Titel | More Information |
| S. Church | Auditing the pre-analytical phase: lessons from 40+ audits across Europe | |
| H. ten Cate | The future of anticoagulation | |
| M. Spannagl | Monitoring new oral anticoagulants-Practical approach | |
| P. Meijer | ECAT survey results on direct oral anticoagulant testing | |
| G. Moore | The new CLSI guideline on Lupus Anticoagulant testing | |
| S. Rosén | How to measure low levels of Factor VIII and IX | |
| H. W. Verbruggen | ECAT survey results for low levels of Factor VIII | |
| C. Kluft | Slope and parallelism of APTT dilution curves: new insights | |
| J. Ruinemans | Establishing reference values – with low number of control samples — | |
| P. Meijer | EQA results for POCT INR testing | |
| Y. Henskens | Application of thrombo-elastography in clinical practice and how to control quality | |
| Ph. G. de Groot | The pathophysiology of Lupus Anticoagulant and the consequences for the laboratory diagnostics | |
| B. Lämmle | ADAMTS13 and the pathogenesis of Thrombotic Thrombocytopenic Purpura (TTP) | |
| R.W.L.M. Niessen | ECAT survey results on ADAMTS13 testing | |
| H. W. Verbruggen | Introduction on Inhibitor Testing | |
| A. Huisman | Procedures and barriers for the introduction of a new or improved method: the example of inhibitor testing | |
| M. van leeuwen | Resistance to change: How to facilitate the implementation of new methods in the lab | |
| M.P.M. de Maat | Quality assurance of the entire diagnostic process | |
| K. Krauel | The pathophysiology of HIT | |
| L. Porcelijn | Heparin Induced Thrombocytopenia; a diagnostic challenge | |
| F.J.L.M. Haas | ECAT survey results for HIT | |
| P.H. Reitsma | The role of molecular biology in the diagnosis of impaired haemostasis | |
8th ECAT International Symposium 2012
| Speaker | Titel | More Information |
| D.M. (Adcock) Funk | Pre-analytical Variables in the Hemostasis Laboratory | |
| Th. VandenDriessche | Gene therapy, the future in hemophilia treatment? | |
| A. Pavlova | Laboratory assays for the measurement of Factor VIII and IX | |
| P. Meijer | The performance of FVIII and FIX measurement in ECAT surveys | |
| H.W. Verbruggen | Factor VIII inhibitor testing – a way to comparable test results | |
| A. Kristoffersen | Interpretation and management of INR results: a case history based survey in 13 countries | |
| H. Mani | Measurement of new oral anticoagulans | |
| M.P.M. de Maat | First experience of ECAT with Measurement of New Oral Anticoagulation Drugs | |
| P.B. Berendes | Is therapeutic quality influenced by choice of thromboplastin? | |
| F. Haas | Age-dependent cut-off values for D-Dimer testing | |
| J. Rosing | Global haemostasis assays: what will be the future? | |
| Ph. G. de Groot | Biochemical background of Lupus Anticoagulant | |
| G. Denas | The SSC algorithm for Lupus testing | |
| G. Moore | The CLSI & BCSH algorithms for Lupus anticoagulant testing | |
| C. Cobbeart | How to assure the quality of POCT testing | |
| P. Meijer | External quality control for CoaguChek XS INR monitors | |
| G. Horowitz | Reference Intervals: Practical Approaches | |
| M. Dardikh | Algoritm for Laboratory Investigations in Case of a prolonged APTT | |
| P. Meijer | Towards diagnostic quality control: a pilot study on acquired inhibitors | |
| E. Ajzner | How do laboratories interpret unexpected APTT prolongation? | |
7th ECAT International Symposium 2010
| Speaker | Titel | More Information |
| M.P.M. de Maat | Biological variation and quality control | |
| J. Meijers | The fibrinolytical system, what and how to measure? | |
| R. Niessen | The results of fibrinolytic surveys | |
| P. Meijer | How to use EQA results in the laboratory? | |
| M. Janssen | Case studies in Thrombophilia | |
| M. Kruip | Case studies in Bleeding disorders | |
| J.O. Westgard | Quality planning in the Haemostasis Laboratory | |
| A. Tripoli | Lupus Anticoagulant: Update of the SSC guidelines | |
| W. Nichols | Lupus Anticoagulant: Do guidelines work in practice? | |
| P. Meijer | Lupus Anticoagulant: Remarkable observations in ECAT surveys | |
| H.W. Verbruggen | Factor VIII Inhibitor Testing, the way to better comparison of test results | |
| H. Bounameaux | An update on new anticoagulation drugs | |
| D. Peetz | Desired tests for monitoring new anticoagulation drugs | |
| C. Kluft | New developments in laboratory tests | |
| A.M.H.P. van den Besselaar | The effect of local ISI calibration on the inter-laboratory variation of the INR | |
| F. Leebeek | The laboratory diagnosis of vWD: current insights | |
| P. Harrison | Laboratory diagnosis of platelet disorders | |
| K. Moffat | Results of the interpretative platelet surveys | |
| C.M. Hackeng | Results of the workshop on platelet function testing | |
| P. Meijer | External quality control: a new decade | |
6th ECAT International Symposium 2008
| Speaker | Titel | More Information |
| M. Galli | The antiphospholipid syndrome: a laboratory phenomenon? | |
| L. Muszbek | The laboratory diagnosis and classification of FXIII deficiencies | |
| R. Niessen | The results of the ECAT pilot study on FXIII testing | |
| A. Stroobants | Test and equipment evaluation, a practical approach | |
| K. de Vooght | Point of care testing for haemostasis. The laboratories point of view | |
| E. Tuddenham | Point of care testing for haemostasis. The clinician’s point of view | |
| L. Rugeri | The results of thromboelastography: does it fit with laboratory testing? | |
| R.M. Bertina | The future of the laboratory diagnosis of thrombofilia | |
| C. Hayward | Platelet function testing: laboratory tests and quality control | |
| C.G. Fraser | Biological variation and analytical quality specifications | |
| M.P.M. de Maat | Biological variation of inflammatory and hemostatic markers | |
| P. Meijer | A scoring system based on the biological variation | |
| E. Favaloro | Inhibitor testing: positive or negative? True or False? | |
| H.W. Verbruggen | The results of the workshop on inhibitor testing | |
| D. van Loon | Laboratory accreditation: the value of quality improvement | |
| A. Greinacher | Laboratory testing for heparin induced thrombocytopenia | |
| P. Meijer | The result of the ECAT HIT surveys | |
| C. Kluft | Generation assays in coagulation and fibrinolysis: Principles and possibilities | |
| W. van Heerde | Clotting and Fibrinolysis: an integrated test system | |
| M. Spannagl | Laboratory assesment of direct and indirect thrombin inhibitors | |